SCHEMBL646876

SCHEMBL646876

CCc1ccc(O)c(C(=O)OC)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 4/20 0.65
CA1 P00915 4/20 0.65
CA2 P00918 4/20 0.65
CA7 P43166 4/20 0.65
CA9 Q16790 4/20 0.65
CA14 Q9ULX7 4/20 0.65
TRPA1 O75762 1/20 0.53
TSHR P16473 2/20 0.53
LMNA P02545 1/20 0.53
KDM4E B2RXH2 2/20 0.53
ALDH1A1 P00352 2/20 0.53
MAPT P10636 2/20 0.53
GAA P10253 2/20 0.53
HPGD P15428 1/20 0.53
ALOX15 P16050 1/20 0.53
HSD17B10 Q99714 1/20 0.53
PTGS2 P35354 1/20 0.53
EGFR P00533 3/20 0.51
NOX4 Q9NPH5 1/20 0.50
PDK2 Q15119 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28991962 0.93 CA12 (0.57) CA12CA1CA2CA7CA9
SCHEMBL10628012 0.89 TSHR (0.67) CA12CA1CA2CA7CA9
SCHEMBL30949369 0.87 CA12 (0.62) CA12CA1CA2CA7CA9
SCHEMBL8887162 0.87 CA12 (0.62) CA12CA1CA2CA7CA9
SCHEMBL10809277 0.86 CA12 (0.61) CA12CA1CA2CA7CA9
SCHEMBL20887338 0.86 CA12 (0.66) CA12CA1CA2CA7CA9
SCHEMBL852964 0.86 CA12 (0.61) CA12CA1CA2CA7CA9
SCHEMBL17201140 0.85 CA12 (0.65) CA12CA1CA2CA7CA9
SCHEMBL20725428 0.85 KAT8 (0.61) CA12CA1CA2CA7CA9
SCHEMBL13332007 0.85 ALDH1A1 (0.56) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117339752-B Mineral separation process of maghemite mixed iron ore 宏大爆破工程集团有限责任公司 2026-05-15 CN claimed
CN-117339752-A Mineral separation process of maghemite mixed iron ore 宏大爆破工程集团有限责任公司 2024-01-05 CN claimed
US-20250320318-A1 OLEFIN POLYMERIZATION CATALYST COMPONENT, CATALYST SYSTEM, PREPOLYMERIZATION CATALYST COMPOSITION AND OLEFIN POLYMERIZATION METHOD CHINA PETROLEUM & CHEM CORP (CN) 2025-10-16 US disclosed
US-12398097-B2 WDR5-MYC inhibitors VANDERBILT UNIVERSITY (US) 2025-08-26 US disclosed
EP-4424720-A1 OLEFIN POLYMERIZATION CATALYST COMPONENT, CATALYST SYSTEM, PREPOLYMERIZATION CATALYST COMPOSITION AND OLEFIN POLYMERIZATION METHOD CHINA PETROLEUM & CHEMICAL CORPORATION (CN) 2024-09-04 EP disclosed
CN-117339752-A Mineral separation process of maghemite mixed iron ore 宏大爆破工程集团有限责任公司 2024-01-05 CN disclosed
WO-2023072179-A1 OLEFIN POLYMERIZATION CATALYST COMPONENT, CATALYST SYSTEM, PREPOLYMERIZATION CATALYST COMPOSITION AND OLEFIN POLYMERIZATION METHOD 中国石油化工股份有限公司 2023-05-04 WO disclosed
CN-116041577-A Olefin polymerization catalyst component, catalyst system, application and olefin polymerization method 中国石油化工股份有限公司 2023-05-02 CN disclosed
US-20230069963-A1 PYRAZOLO[1,5-A]PYRIMIDINE MACROCYCLIC COMPOUND TAISHO PHARMACEUTICAL CO., LTD. (JP) 2023-03-09 US disclosed
US-20220289673-A1 WDR5-MYC INHIBITORS VANDERBILT UNIVERSITY 2022-09-15 US disclosed
EP-3903788-A1 PYRAZOLO[1,5-A]PYRIMIDINE MACROCYCLIC COMPOUND Taisho Pharmaceutical Co., Ltd. (JP) 2021-11-03 EP disclosed
WO-2005095326-A2 2-AMINO- AND 2-THIO-SUBSTITUTED 1,3-DIAMINOPROPANES ELAN PHARMACEUTICALS, INC. (US) 2005-10-13 WO disclosed
EP-1565443-A2 ACETYL 2-HYDROXY-1,3 DIAMINOALKANES Elan Pharmaceuticals, Inc. (US) 2005-08-24 EP disclosed
US-20040180939-A1 Acetyl 2-hydroxy-1, 3-diaminoalkanes ELAN PHARMACEUTICALS INC. 2004-09-16 US disclosed
WO-2004024081-A2 ACETYL 2-HYDROXY-1,3 DIAMINOALKANES ELAN PHARMACEUTICALS, INC. (US) 2004-03-25 WO disclosed
EP-0711286-A1 BENZOXAZINONES AND BENZOTHIAZINONES ENDOWED WITH THERAPEUTIC ACTIVITY ITALFARMACO S.p.A. (IT) 1996-05-15 EP disclosed
WO-1995004048-A1 BENZOXAZINONES AND BENZOTHIAZINONES ENDOWED WITH THERAPEUTIC ACTIVITY ITALFARMACO S.P.A. (IT) 1995-02-09 WO disclosed
EP-0026000-B1 SPIRO COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Takeda Chemical Industries, Ltd. (JP) 1983-05-11 EP disclosed
US-4362740-A ANTICOAGULANTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1982-12-07 US disclosed
EP-0026000-A1 Spiro compounds, process for their preparation and pharmaceutical compositions containing them Takeda Chemical Industries, Ltd. (JP) 1981-04-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220289673-A1 WDR5-MYC INHIBITORS MYC, WDR5, MYCBP CA12 4808/4885CA1 4853/4885CA2 4637/4885
US-20040180939-A1 Acetyl 2-hydroxy-1, 3-diaminoalkanes BACE1, BACE2, APP CA12 1363/4885CA1 71/4885CA2 1963/4885
US-20230069963-A1 PYRAZOLO[1,5-A]PYRIMIDINE MACROCYCLIC COMPOUND ZC3HAV1, ZC3HAV1L, IL5 CA12 3982/4885CA1 4449/4885CA2 2410/4885
US-12398097-B2 WDR5-MYC inhibitors MYC, WDR5, MYCBP CA12 4808/4885CA1 4853/4885CA2 4637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.